Haemophilia (2014), 20 (Suppl. 2), 1–3
PROGRAMME WEDNESDAY, 26 FEBRUARY 09.00-19.00 10.00-12.00
REGISTRATION Multidisciplinary educational session Interactive and multidisciplinary presentation of cases scenarios Initiation of prophylaxis in a young boy Management of an older patient with co-morbidities R. Lassila (FI), E. Santagostino (IT), B. Leenders (BE), C. Harrington (UK), S. Lobet (BE), J. Astermark (SE), C. Hermans (BE)
13.00-14.30
Introduction to the meeting Global haemophilia care: what can be learned from emerging countries? Chairs: J. Astermark (SE), P. de Moerloose (CH) Low-dose replacement and prophylaxis in emerging countries A. Srivastava (IN) Cross-border care: heterogeneity of haemophilia care between countries and its consequences on patients’ management C. Hermans (CH) How can wealthy countries help emerging countries: successes and challenges of the twinning programme P. de Moerloose (CH) Regulatory and Economic developments in Europe: the EHC perspective B. O’Mahony (IE)
14.30-15.00
Coffee Break
15.00-16.00
Focus on inhibitors Chairs: J. Windyga (PL), K. Fischer (NL) Does product type influence the development on inhibitor in PTPs and PUPs? A. Iorio (CA) Inhibitors against clotting factors other than FVIII and FIX P. Collins (UK)
16.30-18.00
Industry-sponsored symposium – PFIZER
18.30-20.00
Industry-sponsored symposium – NOVO NORDISK
20.15-22.15
EAHAD Executive Committee Meeting
THURSDAY, 27 FEBRUARY 08.30-10.00
Prophylaxis: the known and unknown Chairs: R. Lassila (FI), R. D’Oiron (FR) Unresolved issues with primary prophylaxis R. Liesner (UK) Prophylaxis in the era of long-acting products D. Hart (UK) MRI and HJHS: putting sensitive outcome tools into perspective K. Fischer (NL)
10.00-10.30 10.30-12.00
Coffee Break Beyond haemophilia: other bleeding disorders Chairs: C. Hermans (BE), E. Santagostino (IT) Combined clotting factor deficiencies A. Mumford (UK) Bleeding aspects of Ehlers-Danlos disease F. Malfait (BE) New perspectives in the investigation of a mild bleeding tendency K. Freson (BE)
12.00-13.00
Lunch
© 2014 The Authors Haemophilia © 2014 John Wiley & Sons Ltd
1
2
PROGRAMME
13.00-14.30
Laboratory diagnosis of haemophilia and bleeding disorders Chairs: P. A. Holme (NO), A. Rocino (IT) FVIII and IX measurements following old and new products S. Kitchen Modern investigation of platelet functional defects C. Van Geet (BE) Arosenius Lecture - Genetics of haemophilia: recent developments and their impacts on patients care J. Oldenburg (DE)
14.30-16.00
Poster Presentation and Coffee Break Coordinators: C. Hermans (BE), A. Rocino (IT), R. D’Oiron (FR)
16.00-17.30
Industry-sponsored symposium – BAYER
17.30-18.15
General Assembly
19.30
Networking event
FRIDAY, 28 FEBRUARY 08.30-10.00
Industry-sponsored symposium – SOBI BIOGEN IDEC
10.00-10.30
Coffee Break
10.30-12.00
Physiology and therapeutic updates Chairs: J. Windyga (PL), K. Fischer (NL) Influence of glycosylation in haemostasis J. O’Donnell (IE) Pathogen reduction treatment for non-fractionated blood products A. Seltsam (DE) Liver stem cell for the treatment of cotting factor deficiencies: what can we anticipate from the success in inborn errors of metabolism? E. Sokal (BE)
12.00-13.00 13.00-14.15
Lunch Oral presentations Chairs: P. A. Holme (NO), M. Makris (UK) OR01 - Ultrasound screening for early arthropathy in children with moderate and severe haemophilia: first results
Wouter Foppen (NL) OR02 - Factor IX epitope specificity of antibodies that develop in hemophilia B mice expressing murine or human MHC II immunologic background
Paul E. Monahan (USA) OR03 - Hemophilia and von Willebrand disease patients’ perceptions of care at us hemophilia treatment centers
Diane J. Aschman (USA) OR04 - Silencing of protease activated receptors prevents synovitis and cartilage damage following a joint bleed in hemophilic mice
Laurens Nieuwenhuizen (NL) OR05 - Early detection of evolving FVIII inhibitors in a patient with congenital hemophilia A
Christoph J. Hofbauer (AT) OR06 - A service evaluation of outcomes post-intracranial haemorrhage in children with bleeding disorders at one haemophilia centre
Melanie Bladen (UK) Haemophilia (2014), 20 (Suppl. 2), 1–3
© 2014 The Authors Haemophilia © 2014 John Wiley & Sons Ltd
PROGRAMME
3
OR07 - Optimizing prophylaxis: development of an Advate PK calculator and dosing medical device based on a bayesian population PK model
Armin Reininger (AT) 14.15-15.15
Late breaking session Chairs: J. Astermark (SE), P. de Moerloose (CH)
LB01 - The first four year results from the EUHASS project K. Fischer (NL) LB02 - The Certification of Haemophilia Centres in Europe M. Makris (UK) Closing Remarks J. Astermark (SE), P. de Moerloose (CH)
© 2014 The Authors Haemophilia © 2014 John Wiley & Sons Ltd
Haemophilia (2014), 20 (Suppl. 2), 1–3
PROGRAMME WEDNESDAY, 26 FEBRUARY 09.00-19.00 10.00-12.00
REGISTRATION Multidisciplinary educational session Interactive and multidisciplinary presentation of cases scenarios Initiation of prophylaxis in a young boy Management of an older patient with co-morbidities R. Lassila (FI), E. Santagostino (IT), B. Leenders (BE), C. Harrington (UK), S. Lobet (BE), J. Astermark (SE), C. Hermans (BE)
13.00-14.30
Introduction to the meeting Global haemophilia care: what can be learned from emerging countries? Chairs: J. Astermark (SE), P. de Moerloose (CH) Low-dose replacement and prophylaxis in emerging countries A. Srivastava (IN) Cross-border care: heterogeneity of haemophilia care between countries and its consequences on patients’ management C. Hermans (CH) How can wealthy countries help emerging countries: successes and challenges of the twinning programme P. de Moerloose (CH) Regulatory and Economic developments in Europe: the EHC perspective B. O’Mahony (IE)
14.30-15.00
Coffee Break
15.00-16.00
Focus on inhibitors Chairs: J. Windyga (PL), K. Fischer (NL) Does product type influence the development on inhibitor in PTPs and PUPs? A. Iorio (CA) Inhibitors against clotting factors other than FVIII and FIX P. Collins (UK)
16.30-18.00
Industry-sponsored symposium – PFIZER
18.30-20.00
Industry-sponsored symposium – NOVO NORDISK
20.15-22.15
EAHAD Executive Committee Meeting
THURSDAY, 27 FEBRUARY 08.30-10.00
Prophylaxis: the known and unknown Chairs: R. Lassila (FI), R. D’Oiron (FR) Unresolved issues with primary prophylaxis R. Liesner (UK) Prophylaxis in the era of long-acting products D. Hart (UK) MRI and HJHS: putting sensitive outcome tools into perspective K. Fischer (NL)
10.00-10.30 10.30-12.00
Coffee Break Beyond haemophilia: other bleeding disorders Chairs: C. Hermans (BE), E. Santagostino (IT) Combined clotting factor deficiencies A. Mumford (UK) Bleeding aspects of Ehlers-Danlos disease F. Malfait (BE) New perspectives in the investigation of a mild bleeding tendency K. Freson (BE)
12.00-13.00
Lunch
© 2014 The Authors Haemophilia © 2014 John Wiley & Sons Ltd
1
2
PROGRAMME
13.00-14.30
Laboratory diagnosis of haemophilia and bleeding disorders Chairs: P. A. Holme (NO), A. Rocino (IT) FVIII and IX measurements following old and new products S. Kitchen Modern investigation of platelet functional defects C. Van Geet (BE) Arosenius Lecture - Genetics of haemophilia: recent developments and their impacts on patients care J. Oldenburg (DE)
14.30-16.00
Poster Presentation and Coffee Break Coordinators: C. Hermans (BE), A. Rocino (IT), R. D’Oiron (FR)
16.00-17.30
Industry-sponsored symposium – BAYER
17.30-18.15
General Assembly
19.30
Networking event
FRIDAY, 28 FEBRUARY 08.30-10.00
Industry-sponsored symposium – SOBI BIOGEN IDEC
10.00-10.30
Coffee Break
10.30-12.00
Physiology and therapeutic updates Chairs: J. Windyga (PL), K. Fischer (NL) Influence of glycosylation in haemostasis J. O’Donnell (IE) Pathogen reduction treatment for non-fractionated blood products A. Seltsam (DE) Liver stem cell for the treatment of cotting factor deficiencies: what can we anticipate from the success in inborn errors of metabolism? E. Sokal (BE)
12.00-13.00 13.00-14.15
Lunch Oral presentations Chairs: P. A. Holme (NO), M. Makris (UK) OR01 - Ultrasound screening for early arthropathy in children with moderate and severe haemophilia: first results
Wouter Foppen (NL) OR02 - Factor IX epitope specificity of antibodies that develop in hemophilia B mice expressing murine or human MHC II immunologic background
Paul E. Monahan (USA) OR03 - Hemophilia and von Willebrand disease patients’ perceptions of care at us hemophilia treatment centers
Diane J. Aschman (USA) OR04 - Silencing of protease activated receptors prevents synovitis and cartilage damage following a joint bleed in hemophilic mice
Laurens Nieuwenhuizen (NL) OR05 - Early detection of evolving FVIII inhibitors in a patient with congenital hemophilia A
Christoph J. Hofbauer (AT) OR06 - A service evaluation of outcomes post-intracranial haemorrhage in children with bleeding disorders at one haemophilia centre
Melanie Bladen (UK) Haemophilia (2014), 20 (Suppl. 2), 1–3
© 2014 The Authors Haemophilia © 2014 John Wiley & Sons Ltd
PROGRAMME
3
OR07 - Optimizing prophylaxis: development of an Advate PK calculator and dosing medical device based on a bayesian population PK model
Armin Reininger (AT) 14.15-15.15
Late breaking session Chairs: J. Astermark (SE), P. de Moerloose (CH)
LB01 - The first four year results from the EUHASS project K. Fischer (NL) LB02 - The Certification of Haemophilia Centres in Europe M. Makris (UK) Closing Remarks J. Astermark (SE), P. de Moerloose (CH)
© 2014 The Authors Haemophilia © 2014 John Wiley & Sons Ltd
Haemophilia (2014), 20 (Suppl. 2), 1–3
